首页> 美国卫生研究院文献>AAPS PharmSciTech >Development of Novel Biodegradable Polymeric Nanoparticles-in-Microsphere Formulation for Local Plasmid DNA Delivery in the Gastrointestinal Tract
【2h】

Development of Novel Biodegradable Polymeric Nanoparticles-in-Microsphere Formulation for Local Plasmid DNA Delivery in the Gastrointestinal Tract

机译:新型可降解聚合物纳米微粒在胃肠道局部质粒DNA传递的微球配方的发展。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

There is a critical need for development of novel delivery systems to facilitate the translation of nucleic acid-based macromolecules into clinically-viable therapies. The aim of this investigation was to develop and evaluate a novel nanoparticles-in-microsphere oral system (NiMOS) for gene delivery and transfection in specific regions of the gastrointestinal (GI) tract. Plasmid DNA, encoding for the enhanced green fluorescent protein (EGFP-N1), was encapsulated in type B gelatin nanoparticles. NiMOS were prepared by further protecting the DNA-loaded nanoparticles in a poly(epsilon-caprolactone) (PCL) matrix to form microspheres of less than 5.0 μm in diameter. In order to evaluate the biodistribution following oral administration, radiolabeled (111In-labeled) gelatin nanoparticles and NiMOS were administered orally to fasted Balb/C mice. The results of biodistribution studies showed that, while gelatin nanoparticles traversed through the GI tract fairly quickly with more than 54% of the administered dose per gram localizing in the large intestine at the end of 2 h, NiMOS resided in the stomach and small intestine for relatively longer duration. Following oral administration of EGFP-N1 plasmid DNA at 100 μg dose in the control and test formulations, the quantitative and qualitative results presented in this study provide the necessary evidence for transfection potential of NiMOS upon oral administration. After 5 days post-administration, transgene expression in the small and large intestine of mice was observed. Based on these results, NiMOS show significant potential as novel gene delivery vehicle for therapeutic and vaccination purposes.
机译:迫切需要开发新的递送系统以促进将基于核酸的大分子翻译成临床上可行的疗法。这项研究的目的是开发和评估一种新型的微球纳米颗粒口服系统(NiMOS),用于在胃肠道(GI)特定区域进行基因传递和转染。编码增强型绿色荧光蛋白(EGFP-N1)的质粒DNA封装在B型明胶纳米颗粒中。通过进一步保护聚(ε-己内酯)(PCL)基质中的DNA负载纳米颗粒以形成直径小于5.0μm的微球来制备NiMOS。为了评估口服后的生物分布,对禁食的Balb / C小鼠口服了放射性标记的( 111 In标记的)明胶纳米颗粒和NiMOS。生物分布研究的结果表明,虽然明胶纳米颗粒相当快地通过了GI道,并且在2小时结束时定位在大肠中的克剂量超过每克的54%,但NiMOS驻留在胃和小肠中。持续时间相对较长。在对照和测试制剂中以100μg剂量口服EGFP-N1质粒DNA后,本研究中给出的定量和定性结果为口服NiMOS的转染潜力提供了必要的证据。给药5天后,观察到小鼠小肠和大肠中的转基因表达。基于这些结果,NiMOS作为治疗和疫苗接种目的的新型基因传递载体显示出巨大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号